Skip Navigation


NDT Plus Advance Access originally published online on June 5, 2008
NDT Plus 2008 1(4):275-276; doi:10.1093/ndtplus/sfn066
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/4/275    most recent
sfn066v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nakagawa, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

A proposal of the simple guide regarding the conversion ratio from epoetin to darbepoetin alpha in treating haemodialysis patients with renal anaemia

Tetsuya Nakagawa

Dialysis Center, Kamagaya Daiichi Clinic, Kamagaya, Chiba, Japan

Correspondence: E-mail: techima@poppy.ocn.ne.jp

The first 10% of the full text of this article appears below.

Sir,

Darbepoetin alpha (darbepoetin), which has the longest half-time of all the erythropoiesis-stimulating agents (ESAs), is now used world-wide with many advantages for both the patient and the healthcare worker [1,2]. Several recent observations have suggested that in treating renal anaemia the conversion ratio from epoetin to darbepoetin according to the theoretically calculated ‘1 µg darbepoetin = 200 U epoetin’ rule (1:200 rule) leads to an overestimate of the required darbepoetin dose [1]. In particular, in a large-scale . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?